Beijing: Chinese researchers have discovered that histone acetylation-regulated long noncoding RNA known as lysosome cell death regulator (LCDR) plays an important role in tumour survival, suggesting that it could be used as a diagnostic and therapeutic target for lung cancer.
These researchers, led by Prof. GAO Shan of the Chinese Academy of Sciences' Suzhou Institute of Biomedical Engineering and Technology, discovered that knocking down the LCDR in lung cancer cells can accelerate apoptosis. The study's findings were published in the journal 'PNAS.'
The lysosome plays an important role in cellular homeostasis, and its dysregulation has been linked to a wide range of human illnesses, including cancer. LncRNAs are noncoding RNAs with lengths greater than 200 nucleotides that have been linked to cancer symptoms. They interact with DNA, RNA, and protein assemblies to drive cancer growth and survival, including the heterogeneous ribonucleic acid protein (hnRNP) family, which functions as alternative splicing, RNA stability, and translation, among other things. However, it is unknown if lncRNAs and/or hnRNPs play a role in lysosome-mediated cancer survival.
Study finds COVID-19 vaccine doesn’t increase risk of preterm birth
Pfizer's Omicron vaccine could be ready by March: CEO Albert Bourla
Study finds Omicron cases less severe, hospitalisation lower